- AutorIn
- Friederike Pastore
- Hanna Gittinger
- Susanne Raab
- Sebastian Tschuri
- Bianka Ksienzyk
- Nikola P. Konstandin
- Stephanie Schneider
- Maja Rothenberg- Thurley
- Hans-Peter Horny
- Martin Werner
- Maria C. Sauerland
- Susanne Amler
- Dennis Görlich
- Wolfgang E. Berdel
- Bernhard Wörmann
- Jan Braess
- Wolfgang Hiddemann
- Johanna Tischer
- Tobias Herold
- Klaus H. Metzeler
- Karsten Spiekermann
- Titel
- Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:15-qucosa2-1003116
- Quellenangabe
- British journal of haematology : BJHaem
Erscheinungsjahr: 2023
Jahrgang: 202
Heft: 6
Seiten: 1165-1177
ISSN: 0007-1048
E-ISSN: 1365-2141 - Erstveröffentlichung
- 2023
- Abstract (EN)
- Acute megakaryoblastic leukaemia (AMKL) is associated with poor prognosis. Limited information is available on its cytogenetics, molecular genetics and clini- cal outcome. We performed genetic analyses, evaluated prognostic factors and the value of allogeneic haematopoietic stem cell transplantation (allo-HSCT) in a ho- mogenous adult AMKL patient cohort. We retrospectively analysed 38 adult patients with AMKL (median age: 58 years, range: 21–80). Most received intensive treatment in AML Cooperative Group (AMLCG) trials between 2001 and 2016. Cytogenetic data showed an accumulation of adverse risk markers according to ELN 2017 and an unexpected high frequency of structural aberrations on chromosome arm 1q (33%). Most frequently, mutations occurred in TET2 (23%), TP53 (23%), JAK2 (19%), PTPN11 (19%) and RUNX1 (15%). Complete remission rate in 33 patients receiving intensive chemotherapy was 33% and median overall survival (OS) was 33 weeks (95% CI: 21–45). Patients undergoing allo-HSCT (n = 14) had a superior median OS (68 weeks; 95% CI: 11–126) and relapse-free survival (RFS) of 27 weeks (95% CI: 4– 50), although cumulative incidence of relapse after allo-HSCT was high (62%). Theprognosis of AMKL is determined by adverse genetic risk factors and therapy re- sistance. So far allo-HSCT is the only potentially curative treatment option in this dismal AML subgroup.
- Andere Ausgabe
- Erstveröffentlichung
DOI: 10.1111/bjh.18982 - Freie Schlagwörter (EN)
- allo-HSCT, AMKL, AML, AML M7, cytogenetic and molecular landscape, prognosis
- Klassifikation (DDC)
- 610
- Verlag
- Wiley-Blackwell, Hoboken, NY
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:15-qucosa2-1003116
- Veröffentlichungsdatum Qucosa
- 13.11.2025
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY-NC-ND 4.0